Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Breast cancer is now the most commonly diagnosed cancer in women. Worldwide, an estimated 1.67 million cases were diagnosed in 2012, and among men and women combined, breast cancer is now the second most commonly diagnosed cancer after lung cancer (1.82 million cases).
It is of paramount importance to be able to provide good treatment quality to women with breast cancer. A population-based comparison of women diagnosed between 1996 and 1998 found 5-year survival rates of 81% in Europe and 84% in the United States. The 5-year relative survival of female patients with breast cancer in the United States has increased steadily from 75.2% in 1975, 78.4% in 1985, 86.8% in 1995, and 90.6% in 2008. Improvements in breast cancer treatments have been instrumental in achieving this progress, and adjuvant radiation therapy is an important modality in many treatment regimens.
IBA White Paper
*Please refer to the Terms and Conditions of this website when leaving the site and viewing third party content.